REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.
The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
OXNARD, CA / ACCESS Newswire / February 2, 2026 / Quality Dental Services functions as…
Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…
BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…
New online network makes it simple, affordable and stigma-free to connect with licensed therapistsDETROIT, Feb.…
DELRAY BEACH, Fla., Feb. 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Digital X-ray Market…
WINSTON-SALEM, N.C., Feb. 2, 2026 /PRNewswire/ -- mPATH® Health, a digital health company focused on improving…